Indonesia Pharma and Healthcare Sector Report 2026-2027

Indonesia has one of the fastest-growing pharmaceutical and healthcare sectors in ASEAN. The Indonesian government launched a comprehensive national health insurance scheme in 2014 to ensure that all Indonesians have access to healthcare. Almost all Indonesians can now afford healthcare services thanks to the initiative's gradual rollout, which also encourages healthcare providers to build greater capacity to accommodate increased demand. The healthcare system, however, is heavily dependent on imported pharmaceuticals and medical devices, as domestic producers cannot produce enough of the essential supplies hospitals and clinics require. The Indonesian government recently enacted measures to liberalise the investment climate and entice international businesses to set up production facilities in Indonesia to lessen import dependence.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Indonesia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Indonesia
• Crystallise the forces both driving and restraining this sector in Indonesia
• Ascertain Indonesia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Indonesia.
• Build a clear picture of trends, output and consumption for specific sub-sectors